CA2675521C - Human cancer stem cells - Google Patents

Info

Publication number

CA2675521C

CA2675521C CA2675521A CA2675521A CA2675521C CA 2675521 C CA2675521 C CA 2675521C CA 2675521 A CA2675521 A CA 2675521A CA 2675521 A CA2675521 A CA 2675521A CA 2675521 C CA2675521 C CA 2675521C

Authority

CA

Canada

Prior art keywords

stem cells

cells

cell

cancer stem

human

Prior art date

2007-01-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 418
• 210000000130 stem cell Anatomy 0.000 title claims abstract description 412
• 201000011510 cancer Diseases 0.000 title claims abstract description 295
• 238000000034 method Methods 0.000 claims abstract description 86
• 238000012258 culturing Methods 0.000 claims abstract description 16
• 210000004027 cell Anatomy 0.000 claims description 341
• 210000001519 tissue Anatomy 0.000 claims description 105
• 235000015097 nutrients Nutrition 0.000 claims description 78
• 230000012010 growth Effects 0.000 claims description 73
• 206010060862 Prostate cancer Diseases 0.000 claims description 41
• 206010006187 Breast cancer Diseases 0.000 claims description 37
• 208000026310 Breast neoplasm Diseases 0.000 claims description 37
• 201000001514 prostate carcinoma Diseases 0.000 claims description 33
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 32
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 32
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 30
• 201000008275 breast carcinoma Diseases 0.000 claims description 29
• 206010009944 Colon cancer Diseases 0.000 claims description 28
• 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 27
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 26
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 24
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 24
• 201000010989 colorectal carcinoma Diseases 0.000 claims description 23
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 22
• 102100038081 Signal transducer CD24 Human genes 0.000 claims description 22
• 102100032912 CD44 antigen Human genes 0.000 claims description 21
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 21
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 21
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 20
• 206010038038 rectal cancer Diseases 0.000 claims description 20
• 208000020615 rectal carcinoma Diseases 0.000 claims description 20
• 201000005296 lung carcinoma Diseases 0.000 claims description 16
• 239000007787 solid Substances 0.000 claims description 15
• 230000009758 senescence Effects 0.000 claims description 14
• 230000002950 deficient Effects 0.000 claims description 4
• 239000002054 inoculum Substances 0.000 claims description 2
• 239000002458 cell surface marker Substances 0.000 claims 3
• 239000000203 mixture Substances 0.000 description 81
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 80
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 70
• 239000000427 antigen Substances 0.000 description 66
• 108091007433 antigens Proteins 0.000 description 66
• 102000036639 antigens Human genes 0.000 description 66
• 230000001225 therapeutic effect Effects 0.000 description 53
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 50
• 102000004169 proteins and genes Human genes 0.000 description 48
• 238000011282 treatment Methods 0.000 description 43
• 102000004877 Insulin Human genes 0.000 description 40
• 108090001061 Insulin Proteins 0.000 description 40
• 229940125396 insulin Drugs 0.000 description 40
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 39
• 229910052711 selenium Inorganic materials 0.000 description 39
• 239000011669 selenium Substances 0.000 description 39
• 230000014509 gene expression Effects 0.000 description 38
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 38
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 36
• 239000002609 medium Substances 0.000 description 36
• 239000001963 growth medium Substances 0.000 description 35
• SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 33
• 210000002966 serum Anatomy 0.000 description 32
• 241001465754 Metazoa Species 0.000 description 31
• 102400001368 Epidermal growth factor Human genes 0.000 description 29
• 101800003838 Epidermal growth factor Proteins 0.000 description 29
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 29
• 229940116977 epidermal growth factor Drugs 0.000 description 29
• 239000002953 phosphate buffered saline Substances 0.000 description 29
• 229960000890 hydrocortisone Drugs 0.000 description 28
• 239000000758 substrate Substances 0.000 description 28
• 239000002775 capsule Substances 0.000 description 27
• 239000003795 chemical substances by application Substances 0.000 description 27
• 229930182566 Gentamicin Natural products 0.000 description 25
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 25
• 102000004338 Transferrin Human genes 0.000 description 25
• 108090000901 Transferrin Proteins 0.000 description 25
• 238000004113 cell culture Methods 0.000 description 25
• 239000000725 suspension Substances 0.000 description 25
• 239000012581 transferrin Substances 0.000 description 25
• 108010035532 Collagen Proteins 0.000 description 24
• 102000008186 Collagen Human genes 0.000 description 24
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 24
• 108010067306 Fibronectins Proteins 0.000 description 24
• 102000016359 Fibronectins Human genes 0.000 description 24
• 229920001436 collagen Polymers 0.000 description 24
• 206010027476 Metastases Diseases 0.000 description 23
• 230000002163 immunogen Effects 0.000 description 23
• 230000004083 survival effect Effects 0.000 description 22
• 230000001817 pituitary effect Effects 0.000 description 21
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 20
• 208000003569 Central serous chorioretinopathy Diseases 0.000 description 19
• 229940121375 antifungal agent Drugs 0.000 description 19
• 239000003429 antifungal agent Substances 0.000 description 19
• 239000003814 drug Substances 0.000 description 19
• 239000000284 extract Substances 0.000 description 19
• 210000003734 kidney Anatomy 0.000 description 19
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
• 241000699670 Mus sp. Species 0.000 description 18
• 210000004443 dendritic cell Anatomy 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
• 229960005486 vaccine Drugs 0.000 description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
• 206010061289 metastatic neoplasm Diseases 0.000 description 17
• 238000010494 dissociation reaction Methods 0.000 description 16
• 230000005593 dissociations Effects 0.000 description 16
• 210000004881 tumor cell Anatomy 0.000 description 16
• 238000009472 formulation Methods 0.000 description 15
• 238000002955 isolation Methods 0.000 description 15
• 230000001394 metastastic effect Effects 0.000 description 15
• 206010004146 Basal cell carcinoma Diseases 0.000 description 14
• 108010085895 Laminin Proteins 0.000 description 14
• 102000007547 Laminin Human genes 0.000 description 14
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
• 210000002307 prostate Anatomy 0.000 description 14
• 230000005740 tumor formation Effects 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 13
• 229940124597 therapeutic agent Drugs 0.000 description 13
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 12
• 108060003951 Immunoglobulin Proteins 0.000 description 12
• 101710162629 Trypsin inhibitor Proteins 0.000 description 12
• 229940122618 Trypsin inhibitor Drugs 0.000 description 12
• 208000009956 adenocarcinoma Diseases 0.000 description 12
• 239000002246 antineoplastic agent Substances 0.000 description 12
• 239000011575 calcium Substances 0.000 description 12
• 229910052791 calcium Inorganic materials 0.000 description 12
• 238000012512 characterization method Methods 0.000 description 12
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 12
• 201000010099 disease Diseases 0.000 description 12
• 239000003102 growth factor Substances 0.000 description 12
• 102000018358 immunoglobulin Human genes 0.000 description 12
• 238000002347 injection Methods 0.000 description 12
• 239000007924 injection Substances 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 230000001613 neoplastic effect Effects 0.000 description 12
• 238000001959 radiotherapy Methods 0.000 description 12
• 239000002753 trypsin inhibitor Substances 0.000 description 12
• 108090000695 Cytokines Proteins 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 11
• 239000007640 basal medium Substances 0.000 description 11
• 238000002512 chemotherapy Methods 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000028993 immune response Effects 0.000 description 11
• 239000008188 pellet Substances 0.000 description 11
• 238000001356 surgical procedure Methods 0.000 description 11
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
• 244000068988 Glycine max Species 0.000 description 10
• 235000010469 Glycine max Nutrition 0.000 description 10
• -1 PTA-6059) Proteins 0.000 description 10
• 239000003242 anti bacterial agent Substances 0.000 description 10
• 239000006285 cell suspension Substances 0.000 description 10
• 238000005119 centrifugation Methods 0.000 description 10
• 210000001072 colon Anatomy 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 230000002255 enzymatic effect Effects 0.000 description 10
• 239000012091 fetal bovine serum Substances 0.000 description 10
• 238000002513 implantation Methods 0.000 description 10
• 239000000186 progesterone Substances 0.000 description 10
• 229960003387 progesterone Drugs 0.000 description 10
• 201000009030 Carcinoma Diseases 0.000 description 9
• 229930182555 Penicillin Natural products 0.000 description 9
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
• 229930003427 Vitamin E Natural products 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 230000003115 biocidal effect Effects 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
• 210000000987 immune system Anatomy 0.000 description 9
• 238000002649 immunization Methods 0.000 description 9
• 230000003053 immunization Effects 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 238000004519 manufacturing process Methods 0.000 description 9
• 230000009401 metastasis Effects 0.000 description 9
• 229940049954 penicillin Drugs 0.000 description 9
• 229960005322 streptomycin Drugs 0.000 description 9
• 230000000153 supplemental effect Effects 0.000 description 9
• 239000011709 vitamin E Substances 0.000 description 9
• 229940046009 vitamin E Drugs 0.000 description 9
• 235000019165 vitamin E Nutrition 0.000 description 9
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
• 229940088710 antibiotic agent Drugs 0.000 description 8
• 238000004166 bioassay Methods 0.000 description 8
• 229940030156 cell vaccine Drugs 0.000 description 8
• 229940127089 cytotoxic agent Drugs 0.000 description 8
• 238000009169 immunotherapy Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 210000004698 lymphocyte Anatomy 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 239000006228 supernatant Substances 0.000 description 8
• 108010039627 Aprotinin Proteins 0.000 description 7
• 108090000556 Neuregulin-1 Proteins 0.000 description 7
• 102400000058 Neuregulin-1 Human genes 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 229960004405 aprotinin Drugs 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 238000000684 flow cytometry Methods 0.000 description 7
• 210000004408 hybridoma Anatomy 0.000 description 7
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 7
• 230000005855 radiation Effects 0.000 description 7
• 238000003753 real-time PCR Methods 0.000 description 7
• 206010041823 squamous cell carcinoma Diseases 0.000 description 7
• 229960003604 testosterone Drugs 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 102100040120 Prominin-1 Human genes 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 230000000890 antigenic effect Effects 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 239000012634 fragment Substances 0.000 description 6
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
• 238000012423 maintenance Methods 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 108010052285 Membrane Proteins Proteins 0.000 description 5
• 101710160107 Outer membrane protein A Proteins 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 240000003186 Stachytarpheta cayennensis Species 0.000 description 5
• 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 230000003833 cell viability Effects 0.000 description 5
• 208000029742 colonic neoplasm Diseases 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 238000007876 drug discovery Methods 0.000 description 5
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 5
• 229960001101 ifosfamide Drugs 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 208000020816 lung neoplasm Diseases 0.000 description 5
• 210000005170 neoplastic cell Anatomy 0.000 description 5
• 238000007747 plating Methods 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 210000002435 tendon Anatomy 0.000 description 5
• 208000008732 thymoma Diseases 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 102100038078 CD276 antigen Human genes 0.000 description 4
• 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 230000003698 anagen phase Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000001093 anti-cancer Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 229960004562 carboplatin Drugs 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 229960004679 doxorubicin Drugs 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 229960005420 etoposide Drugs 0.000 description 4
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• 238000013415 human tumor xenograft model Methods 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 108010082117 matrigel Proteins 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 210000000716 merkel cell Anatomy 0.000 description 4
• 208000037819 metastatic cancer Diseases 0.000 description 4
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 229960001592 paclitaxel Drugs 0.000 description 4
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 238000010257 thawing Methods 0.000 description 4
• 206010044412 transitional cell carcinoma Diseases 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• 238000002255 vaccination Methods 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 206010008342 Cervix carcinoma Diseases 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 3
• 239000000232 Lipid Bilayer Substances 0.000 description 3
• 102000018697 Membrane Proteins Human genes 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 102000015336 Nerve Growth Factor Human genes 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 201000009365 Thymic carcinoma Diseases 0.000 description 3
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 108010031318 Vitronectin Proteins 0.000 description 3
• 102100035140 Vitronectin Human genes 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 210000000612 antigen-presenting cell Anatomy 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 238000002725 brachytherapy Methods 0.000 description 3
• 239000002771 cell marker Substances 0.000 description 3
• 201000010881 cervical cancer Diseases 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 239000003636 conditioned culture medium Substances 0.000 description 3
• 238000002681 cryosurgery Methods 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 238000009509 drug development Methods 0.000 description 3
• 238000009261 endocrine therapy Methods 0.000 description 3
• 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 238000010195 expression analysis Methods 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• 238000001794 hormone therapy Methods 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 201000005249 lung adenocarcinoma Diseases 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 230000000877 morphologic effect Effects 0.000 description 3
• 229940053128 nerve growth factor Drugs 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• 230000004850 protein–protein interaction Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• 229960003048 vinblastine Drugs 0.000 description 3
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
• 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 201000008162 B cell deficiency Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102100024210 CD166 antigen Human genes 0.000 description 2
• 108090000007 Carboxypeptidase M Proteins 0.000 description 2
• 102100032936 Carboxypeptidase M Human genes 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 102000051096 EphA2 Receptor Human genes 0.000 description 2
• 108010055196 EphA2 Receptor Proteins 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 108700012941 GNRH1 Proteins 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001050321 Homo sapiens Junctional adhesion molecule C Proteins 0.000 description 2
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 102100023429 Junctional adhesion molecule C Human genes 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 108091054438 MHC class II family Proteins 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 102100039373 Membrane cofactor protein Human genes 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• 101150042817 NFS1 gene Proteins 0.000 description 2
• 102100035488 Nectin-2 Human genes 0.000 description 2
• 102000004664 Oncostatin M Receptor beta Subunit Human genes 0.000 description 2
• 108010003767 Oncostatin M Receptor beta Subunit Proteins 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 101100126298 Rickettsia conorii (strain ATCC VR-613 / Malish 7) iscS gene Proteins 0.000 description 2
• 238000011579 SCID mouse model Methods 0.000 description 2
• 108091006629 SLC13A2 Proteins 0.000 description 2
• 101150114492 SPL1 gene Proteins 0.000 description 2
• 238000003070 Statistical process control Methods 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• 108010033576 Transferrin Receptors Proteins 0.000 description 2
• 102000007238 Transferrin Receptors Human genes 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 238000009167 androgen deprivation therapy Methods 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000002710 external beam radiation therapy Methods 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 235000021062 nutrient metabolism Nutrition 0.000 description 2
• 210000000277 pancreatic duct Anatomy 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 108091005706 peripheral membrane proteins Proteins 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 230000000379 polymerizing effect Effects 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 208000023958 prostate neoplasm Diseases 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000003439 radiotherapeutic effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 208000000649 small cell carcinoma Diseases 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 238000004114 suspension culture Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
• 229950004616 tribromoethanol Drugs 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 238000009736 wetting Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
• 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
• 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
• 208000001783 Adamantinoma Diseases 0.000 description 1
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 208000017234 Bone cyst Diseases 0.000 description 1
• 101710185679 CD276 antigen Proteins 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000001843 Carotid Body Tumor Diseases 0.000 description 1
• 102000005572 Cathepsin A Human genes 0.000 description 1
• 108010059081 Cathepsin A Proteins 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 108010048623 Collagen Receptors Proteins 0.000 description 1
• 241000037164 Collema parvum Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108010045583 Desmoglein 2 Proteins 0.000 description 1
• 102000005707 Desmoglein 2 Human genes 0.000 description 1
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
• 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
• 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 102000000507 Integrin alpha2 Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010068116 Metastatic uterine cancer Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 101100117488 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mip-1 gene Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 102000000017 Patched Receptors Human genes 0.000 description 1
• 108010069873 Patched Receptors Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 208000006994 Precancerous Conditions Diseases 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 241000508269 Psidium Species 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• 206010073334 Rhabdoid tumour Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 201000001322 T cell deficiency Diseases 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 208000019502 Thymic epithelial neoplasm Diseases 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000726445 Viroids Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 1
• 102100022224 Y-box-binding protein 1 Human genes 0.000 description 1
• LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
• 108010023617 abarelix Proteins 0.000 description 1
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
• 229960002184 abarelix Drugs 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 208000012080 benign lipomatous neoplasm Diseases 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 239000003181 biological factor Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
• 201000010983 breast ductal carcinoma Diseases 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 238000009172 cell transfer therapy Methods 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 238000011281 clinical therapy Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000005516 coenzyme A Substances 0.000 description 1
• 229940093530 coenzyme a Drugs 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 210000000188 diaphragm Anatomy 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 108010007093 dispase Proteins 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
• 229950008454 favipiravir Drugs 0.000 description 1
• 210000000604 fetal stem cell Anatomy 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 201000010073 fibrogenesis imperfecta ossium Diseases 0.000 description 1
• 201000010103 fibrous dysplasia Diseases 0.000 description 1
• 239000002657 fibrous material Substances 0.000 description 1
• 238000005206 flow analysis Methods 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 239000002474 gonadorelin antagonist Substances 0.000 description 1
• 230000009629 growth pathway Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 108700020746 histrelin Proteins 0.000 description 1
• 229960002193 histrelin Drugs 0.000 description 1
• HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 238000009802 hysterectomy Methods 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 238000002721 intensity-modulated radiation therapy Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 244000000056 intracellular parasite Species 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 201000005252 lipomatous cancer Diseases 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 239000007758 minimum essential medium Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000003990 molecular pathway Effects 0.000 description 1
• 238000004264 monolayer culture Methods 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 229940031348 multivalent vaccine Drugs 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 210000002747 omentum Anatomy 0.000 description 1
• 238000011474 orchiectomy Methods 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
• 239000004810 polytetrafluoroethylene Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000002661 proton therapy Methods 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 238000009803 radical hysterectomy Methods 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 229940091258 selenium supplement Drugs 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 201000011096 spinal cancer Diseases 0.000 description 1
• 208000014618 spinal cord cancer Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 210000000603 stem cell niche Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 208000033079 susceptibility to 2 basal cell carcinoma Diseases 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 238000013334 tissue model Methods 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229960004824 triptorelin Drugs 0.000 description 1
• VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 208000025443 tumor of adipose tissue Diseases 0.000 description 1
• 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 201000009542 type C thymoma Diseases 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 239000002691 unilamellar liposome Substances 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1
• GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1